The global biosimilars market was valued at $23.8 billion in 2023. The market is expected to grow from $28.5 billion in 2024 to $69.2 billion by 2029, at a compound annual growth rate (CAGR) of 19.4% from 2024 through 2029.
The European biosimilars market is expected to grow from $13.0 billion in 2024 to $31.6 billion by 2029, at a CAGR of 19.4% from 2024 through 2029.
The North American biosimilars market is expected to grow from $9.2 billion in 2024 to $22.9 billion by 2029, at a CAGR of 20.1% from 2024 through 2029.
Report Scope
This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.
For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases. Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.
The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization's business segments, financials, product portfolios and recent developments.
Report Includes
142 data tables and 74 additional tables
An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region
Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of macroeconomic factors
Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product
Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
An analysis of key patent publications, grants and applications in biosimilars
Analysis of the competitive landscape featuring companies' market shares, strategic alliances, M&A activity and a venture funding outlook
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies
Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Insights
Chapter 2 Market Overview
Introduction
Terminology of Biosimilars
Key Terms in Biosimilars
WHO Guidelines on Evaluation of Biosimilars
Pharmacovigilance/Post-Approval Monitoring
Biosimilars Vs. Biobetters
Popular Types of Biosimilars
Recombinant Hormones
Recombinant Growth Factors
Monoclonal Antibodies (mAbs)
Fusion Proteins
Interferons
Low Molecular Weight Heparins (LMWHs)
Chapter 3 Market Dynamics
Introduction
Market Drivers
Patent Expirations of Major Biologics
Cost-effectiveness and Healthcare Savings
Market Restraints
Intellectual Property and Legal Issues
Manufacturing and Supply Chain Complexities
Market Opportunities
Increasing Access, Adoption and Awareness
Emerging Markets
Chapter 4 Emerging Technologies
Advanced Analytical Techniques
Single-use Bioreactors
Cell Line Engineering and Expression Systems
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Global Biosimilars Market, by Product Type
Monoclonal Antibodies
Recombinant Growth Factors
Recombinant Hormones
Fusion Protein
Others
Global Biosimilars Market, by Therapeutic Application
Cancer and Related Disorders
Autoimmune and Inflammatory Diseases
Diabetes
Anemia
Growth Hormone Deficiency
Other Diseases
Geographic Breakdown
Global Biosimilars Market, by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World (RoW)
Chapter 6 Competitive Landscape and Patent Analysis
Overview
Key Market Leaders
Emerging Players
Strategic Analysis
Challenges and Future Trends
Patent Analysis
Patent Regulations in Favor of Branded Biologics
Market Exclusivity
Chapter 7 Regulatory Aspects
Overview
Biosimilar Regulations in Europe
Biosimilar Regulations in the U.S.
Principle of Exclusivity
Biosimilar Regulations in China
Chapter 8 Sustainability in the Global Biosimilars Market: An ESG Perspective